This website uses cookies to store user session information. By using our website you consent to our terms of use. Read more
I agree
"Horizon 2020 Programme" project MP1GI20003R
MP1GI20003R "Predicting comorbid cardiovascular disease in individuals with mental disorder by decoding disease mechanisms (1.01.2020−31.12.2023)", Lili Azin Milani, University of Tartu, Institute of Genomics.
MP1GI20003R
Südame-veresoonkonna haiguste ja vaimsete häirete komorbiidsuse ennustamine
Predicting comorbid cardiovascular disease in individuals with mental disorder by decoding disease mechanisms
CoMorMent
1.01.2020
31.12.2023
R&D project
Horizon 2020 Programme
ETIS classificationSubfieldCERCS classificationFrascati Manual classificationPercent
1. Biosciences and Environment1.3. GeneticsB220 Genetics, cytogenetics 1.6 Biological sciences50,0
3. Health3.1. BiomedicineB726 Clinical biology 3.1 Basic medicine50,0
InstitutionRolePeriod
University of Tartu, Institute of Genomicscoordinaator01.01.2020−31.12.2023
InstitutionCountryType
Euroopa Komisjon
PeriodSum
01.01.2020−31.12.2023553 125,00 EUR
553 125,00 EUR

Projekti käigus analüüsitakse, kuidas vaimsete häirete riske suurendavad geenimuutused mõjutavad südame-veresoonkonna haigustesse haigestumist elustiilivalikute kaudu. Tulemusena töötatakse välja südame-veresoonkonna haiguste ennetusmeetodid.
Comorbid cardiovascular disease in people with severe mental disorders is a major public health concern and poses a considerable financial burden on European Health Care. The CoMorMent project will uncover mechanisms underlying the higher incidence of cardiovascular disease in people with mental disorders. This project builds on our recent findings that genetic variation that affects genes expressed in the brain and which increase the risk of mental disorders also impact lifestyle and behaviour (e.g. diet, exercise, and smoking) that increase cardiovascular risk. The project will identify molecular mechanisms common to mental disorders and unhealthy lifestyles that increase the risk of cardiovascular disease. We will take advantage of our genotyped biobank samples united with large national registries with information about disease trajectories and comorbidity in over 1.8 million people. The “big data” available to CoMorMent means that we can apply new statistical tools to discover novel sequence variants conferring risk of both mental disorders and cardiovascular diseases and determine how these may be mediated by lifestyle or behaviour. We will characterize the underlying mechanisms by identifying accompanying structural brain changes and body fat composition from MRI data in combination with gene expression and functional studies. The CoMorMent multidisciplinary expert team in clinical science (cardiology, psychiatry), genetic epidemiology, molecular genetics, and neuroscience combined with experts in machine learning and computation will generate findings that will form the basis of novel stratification and prediction tools, which will be tested and validated in clinical samples. Thus, CoMorMent will form the basis for a new approach in clinical studies by providing precision medicine tools for clinical implementation to remediate a major public health issue.
Description in EstonianPercent
Basic Research50,0
Applied Research50,0
InstitutionRoleCountryTypeComment
ADVANCED MR ANALYTICS AB (AMRA)partnerSwedenenterprise
ISLENSK ERFDAGREINING EHF (DeCode)partnerIcelandenterprise
KAROLINSKA INSTITUTETpartnerSwedenR&D institution
Multi Modal Imaging Services Corporation (HealthLytix)partnerUnited Statesenterprise
OSLO UNIVERSITETSSYKEHUS HF (juhtpartneriga seotud kolmas osapool)partnerNorway
REGION HOVEDSTADENpartnerDenmark
THE UNIVERSITY OF EDINBURGHpartnerGreat Britainuniversity
UNIVERSITY OF OSLOcoordinaatorNorwayuniversity